Heterogeneity in the Ki-67 Index of Neuroendocrine Tumors Abstract #961

Introduction: Tumor heterogeneity due to tumor evolution is becoming more widely recognised. Neuroendocrine tumors (NET) are routinely graded using the Ki-67 index based on a single tumor location, however, this could lead to undergrading if the Ki-67 index is higher at the metastatic site.
Aim(s): Assess the extent of Ki-67 index heterogeneity in NET.
Materials and methods: Ki-67 index was assessed in 31 NET patients, and determined in all lesions with available tissue. Immunohistochemical staining was done and the Ki-67 index determined according to standard criteria. In 23 patients, tissue was available from the primary and metastatic lesions and in two patients from multiple pancreatic lesions. Sections were taken at five points spaced evenly across metastasis from six explant livers from NET patients.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Helen Miller

To read results and conclusion, please login ...

Further abstracts you may be interested in

#682 Neuroendocrine Tumors, Searching for New Prognostic Biomarkers
Introduction: Neuroendocrine tumors (NET) of the digestive system were once considered relatively rare, however, the incidence is increasing. New prognostic biomarkers are needed for assessment of tumor behavior to inform patient treatment and improve outcome. The proliferation marker, Ki-67, is used for NET grading. Although classified as low grade, some tumors actually develop metastases.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Helen Miller
#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases
Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Deyanira González Devia
#2871 Increase of Ki-67 Index over Time and Influence on All-Cause Mortality in Patients with Neuroendocrine Neoplasms (NEN)
Introduction: Increase of Ki-67 index in NEN over time in relation to progression and a potential influence on prognosis is scarcely studied.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD Pernille Holmager
#3036 Can Ki-67 with 5.5% Be Better in Predicting Prognosis for Well Differentiated Pancreatic Neuroendocrine Tumors?
Introduction: Pancreatic neuroendocrine tumors (NETs) are rare malignancies, Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis of neuroendocrine tumors. However, the ideal grading method for G1/G2 remains controversial.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Prof. Huang-Ying Tan
Authors: Yuan B, Chen Y Y, Zhang P, Wang X, ...
#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?
Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Teresa Alonso Gordoa